Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Abigail DeLoach, Michael Cozart, Arianna Kiaei & Mahmoud Kiaei. (2015) A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies. Expert Opinion on Drug Discovery 10:10, pages 1099-1118.
Read now
Read now
A. Kumar, V. Kumar, S. K. Singh, S. Muthuswamy & S. Agarwal. (2014) Imbalanced oxidant and antioxidant ratio in myotonic dystrophy type 1. Free Radical Research 48:4, pages 503-510.
Read now
Read now
Philippe Corcia & Paul H Gordon. (2012) Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Therapeutics and Clinical Risk Management 8, pages 359-366.
Read now
Read now
Ali Aamer Habib & Hiroshi Mitsumoto. (2011) Emerging drugs for amyotrophic lateral sclerosis. Expert Opinion on Emerging Drugs 16:3, pages 537-558.
Read now
Read now
Rodrigo CL Edelmuth, Michael A Nitsche, Linamara Battistella & Felipe Fregni. (2010) Why do some promising brain-stimulation devices fail the next steps of clinical development?. Expert Review of Medical Devices 7:1, pages 67-97.
Read now
Read now
Stefano Zoccolella, Andrea Santamato & Paolo Lamberti. (2009) Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatric Disease and Treatment 5, pages 577-595.
Read now
Read now
Antonio Toscano, Sonia Messina, Giuseppe M. Campo, Rita Di Leo, Olimpia Musumeci, Carmelo Rodolico, Mohamed Aguennouz, Grazia Annesi, Corrado Messina & Giuseppe Vita. (2005) Oxidative stress in myotonic dystrophy type 1. Free Radical Research 39:7, pages 771-776.
Read now
Read now
Articles from other publishers (20)
Belgin Sever, Halilibrahim Ciftci, Hasan DeMirci, Hilal Sever, Firdevs Ocak, Burak Yulug, Hiroshi Tateishi, Takahisa Tateishi, Masami Otsuka, Mikako Fujita & Ayşe Nazlı Başak. (2022) Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 23:5, pages 2400.
Crossref
Crossref
Anamaria Jurcau. (2021) Insights into the Pathogenesis of Neurodegenerative Diseases: Focus on Mitochondrial Dysfunction and Oxidative Stress. International Journal of Molecular Sciences 22:21, pages 11847.
Crossref
Crossref
Elena Obrador, Rosario Salvador-Palmer, Rafael López-Blanch, Ali Jihad-Jebbar, Soraya L. Vallés & José M. Estrela. (2021) The Link between Oxidative Stress, Redox Status, Bioenergetics and Mitochondria in the Pathophysiology of ALS. International Journal of Molecular Sciences 22:12, pages 6352.
Crossref
Crossref
Christine Péladeau & Jagdeep K. Sandhu. (2021) Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases. International Journal of Molecular Sciences 22:11, pages 6068.
Crossref
Crossref
Teresa Cunha-Oliveira, Liliana Montezinho, Catarina Mendes, Omidreza Firuzi, Luciano Saso, Paulo J. Oliveira & Filomena S. G. Silva. (2020) Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention. Oxidative Medicine and Cellular Longevity 2020, pages 1-29.
Crossref
Crossref
Vijay Kumar, Tara Kashav & Md. Imtaiyaz Hassan. 2019. Pathology, Prevention and Therapeutics of Neurodegenerative Disease. Pathology, Prevention and Therapeutics of Neurodegenerative Disease
207
224
.
Teodorico C. Ramalho, Alexandre A. de Castro, Tássia S. Tavares, Maria C. Silva, Daniela R. Silva, Pedro H. Cesar, Lucas A. Santos, Elaine F.F. da Cunha, Eugenie Nepovimova & Kamil Kuca. (2018) Insights into the pharmaceuticals and mechanisms of neurological orphan diseases: Current Status and future expectations. Progress in Neurobiology 169, pages 135-157.
Crossref
Crossref
Vijay Kumar, Asimul Islam, Md. Imtaiyaz Hassan & Faizan Ahmad. (2016) Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning. European Journal of Medicinal Chemistry 121, pages 903-917.
Crossref
Crossref
Aparna Sharma, Anu Mary Varghese, Kalyan Vijaylakshmi, Rajendrarao Sumitha, V. K. Prasanna, S. Shruthi, B. K. Chandrasekhar Sagar, Keshava K. Datta, Harsha Gowda, Atchayaram Nalini, Phalguni Anand Alladi, Rita Christopher, Talakad N. Sathyaprabha, Trichur R. Raju & M. M. Srinivas Bharath. (2015) Cerebrospinal Fluid from Sporadic Amyotrophic Lateral Sclerosis Patients Induces Mitochondrial and Lysosomal Dysfunction. Neurochemical Research 41:5, pages 965-984.
Crossref
Crossref
Keiichi Shibagaki, Kazuyoshi Okamoto, Osamu Katsuta & Masatsugu Nakamura. (2015) Beneficial protective effect of pramipexole on light-induced retinal damage in mice. Experimental Eye Research 139, pages 64-72.
Crossref
Crossref
Ivana Matic, Daniela Strobbe, Michele Frison & Michelangelo Campanella. (2015) Controlled and Impaired Mitochondrial Quality in Neurons: Molecular Physiology and Prospective Pharmacology. Pharmacological Research 99, pages 410-424.
Crossref
Crossref
Michael Jablonski, David S. Miller, Piera Pasinelli & Davide Trotti. (2015) ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis. Brain Research 1607, pages 1-14.
Crossref
Crossref
H Muyderman & T Chen. (2014) Mitochondrial dysfunction in amyotrophic lateral sclerosis - a valid pharmacological target?. British Journal of Pharmacology 171:8, pages 2191-2205.
Crossref
Crossref
Michael E. Bozik, James L. Mather, William G. Kramer, Valentin K. Gribkoff & Evan W. Ingersoll. (2011) Safety, Tolerability, and Pharmacokinetics of KNS-760704 (Dexpramipexole) in Healthy Adult Subjects. The Journal of Clinical Pharmacology 51:8, pages 1177-1185.
Crossref
Crossref
Peter I. Joyce, Pietro Fratta, Elizabeth M. C. Fisher & Abraham Acevedo-Arozena. (2011) SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mammalian Genome 22:7-8, pages 420-448.
Crossref
Crossref
Salvatore Grosso, Serafina Perrone, Mariangela Longini, Carlo Bruno, Claudio Minetti, Diego Gazzolo, Paolo Balestri & Giuseppe Buonocore. (2008) Isoprostanes in dystrophinopathy: Evidence of increased oxidative stress. Brain and Development 30:6, pages 391-395.
Crossref
Crossref
Daniela Uberti, Irene Bianchi, Luca Olivari, Giulia Ferrari-Toninelli, Sara A. Bonini & Maurizio Memo. (2007) Dopaminergic Agonists: Possible Neurorescue Drugs Endowed with Independent and Synergistic Multisites of Action. Neurochemical Research 32:10, pages 1726-1729.
Crossref
Crossref
Seong-Ho Koh, Sang Mok Lee, Hyun Young Kim, Kyu-Yong Lee, Young Joo Lee, Hee-Tae Kim, Juhan Kim, Myung-Ho Kim, Myung Sil Hwang, Chiwon Song, Ki-Wha Yang, Kwang Woo Lee, Seung Hyun Kim & Ok-Hee Kim. (2006) The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neuroscience Letters 395:2, pages 103-107.
Crossref
Crossref
R. Danzeisen, B. Schwalenstoecker, F. Gillardon, E. Buerger, V. Krzykalla, K. Klinder, L. Schild, B. Hengerer, A. C. Ludolph, C. Dorner-Ciossek & L. Kussmaul. (2006) Targeted Antioxidative and Neuroprotective Properties of the Dopamine Agonist Pramipexole and Its Nondopaminergic Enantiomer SND919CL2x [(+)2-Amino-4,5,6,7-tetrahydro-6-lpropylamino-benzathiazole Dihydrochloride]. Journal of Pharmacology and Experimental Therapeutics 316:1, pages 189-199.
Crossref
Crossref
Edith G McGeer & Patrick L McGeer. (2005) Pharmacologic Approaches to the Treatment of Amyotrophic Lateral Sclerosis. BioDrugs 19:1, pages 31-37.
Crossref
Crossref